## Martha S Foiani

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9171734/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Molecular biomarkers of Alzheimer's disease: progress and prospects. DMM Disease Models and Mechanisms, 2018, 11, .	2.4	163
2	Plasma glial fibrillary acidic protein is raised in progranulin-associated frontotemporal dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 263-270.	1.9	106
3	Cerebrospinal fluid in the differential diagnosis of Alzheimer's disease: clinical utility of an extended panel of biomarkers in a specialist cognitive clinic. Alzheimer's Research and Therapy, 2018, 10, 32.	6.2	79
4	Serum neurofilament light levels correlate with severity measures and neurodegeneration markers in autosomal dominant Alzheimer's disease. Alzheimer's Research and Therapy, 2018, 10, 113.	6.2	54
5	Plasma Neurofilament Light for Prediction of Disease Progression in Familial Frontotemporal Lobar Degeneration. Neurology, 2021, 96, e2296-e2312.	1.1	52
6	Cerebrospinal fluid soluble TREM2 levels in frontotemporal dementia differ by genetic and pathological subgroup. Alzheimer's Research and Therapy, 2018, 10, 79.	6.2	43
7	Plasma tau is increased in frontotemporal dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 804-807.	1.9	41
8	Muscle and not neuronal biomarkers correlate with severity in spinal and bulbar muscular atrophy. Neurology, 2019, 92, e1205-e1211.	1.1	41
9	Cerebrospinal Fluid Biomarkers in Cerebral Amyloid Angiopathy. Journal of Alzheimer's Disease, 2020, 74, 1189-1201.	2.6	38
10	White matter hyperintensities in progranulin-associated frontotemporal dementia: A longitudinal GENFI study. NeuroImage: Clinical, 2019, 24, 102077.	2.7	27
11	Searching for novel cerebrospinal fluid biomarkers of tau pathology in frontotemporal dementia: an elusive quest. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 740-746.	1.9	23
12	Plasma glial fibrillary acidic protein and neurofilament light chain, but not tau, are biomarkers of sports-related mild traumatic brain injury. Brain Communications, 2020, 2, fcaa137.	3.3	22
13	Amyloid β peptides are differentially vulnerable to preanalytical surface exposure, an effect incompletely mitigated by the use of ratios. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 311-321.	2.4	21
14	Plasma Neurofilament Light as a Biomarker of Neurological Involvement in Wilson's Disease. Movement Disorders, 2021, 36, 503-508.	3.9	15
15	Plasma glial fibrillary acidic protein and neurofilament light chain are measures of disease severity in semantic variant primary progressive aphasia. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 455-456.	1.9	11
16	Interlaboratory validation of cerebrospinal fluid αâ€synuclein quantification in the diagnosis of sporadic Creutzfeldtâ€akob disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 461-470.	2.4	7
17	Effect of Spinal Manometers on Cerebrospinal Fluid Amyloid-Î <sup>2</sup> Concentration. Journal of Alzheimer's Disease, 2017, 56, 885-891.	2.6	6
18	Cerebrospinal fluid metallomics in cerebral amyloid angiopathy: an exploratory analysis. Journal of Neurology, 2022, 269, 1470-1475.	3.6	5

#	Article	IF	CITATIONS
19	[P2–254]: SERUM FERRITIN IS INCREASED IN A SUBSET OF PATIENTS WITH FRONTOTEMPORAL DEMENTIA. Alzheimer's and Dementia, 2017, 13, P710.	0.8	0
20	O3â€09â€03: SERUM NEUROFILAMENT LIGHT LEVELS CORRELATE WITH SEVERITY MEASURES AND NEURODEGENERATION MARKERS IN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1037.	0.8	0
21	Microglial activation: A process potentially related to Alzheimer's disease and lateâ€life major depression. Alzheimer's and Dementia, 2020, 16, e041950.	0.8	0